Litigation Details for Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited (S.D.N.Y. 2024)

Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited (S.D.N.Y. 2024)

Docket		Date Filed	2024-07-02
Court	District Court, S.D. New York	Date Terminated	2024-12-10
Cause	35:271 Patent Infringement	Assigned To	Cathy Seibel
Jury Demand	None	Referred To
Patents	10,238,620; 11,110,074; 7,915,307; 8,513,299; 9,107,898; 9,486,437; 9,572,814; 9,861,607
Link to Docket	External link to docket

Details for Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited (S.D.N.Y. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-07-02				External link to document

Litigation summary and analysis for: Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited (S.D.N.Y. 2024)

Last updated: July 14, 2026

Litigation summary and analysis for Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited, 7:24-cv-05040

Executive summary: The case Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited (7:24-cv-05040) is filed as a patent infringement action tied to FDA-driven generic or authorized-competitor entry. The docket number indicates a U.S. District Court filing in 2024; however, a litigation-specific outcome profile (claims asserted, asserted patents, Paragraph IV basis, proposed product details, and any settlement terms) cannot be produced from the information provided here.

What is the case caption, docket number, and court for Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited (7:24-cv-05040)?

Case: Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited
Docket: 7:24-cv-05040
Jurisdiction: Federal district court (exact district and judge not provided)

What procedural posture typically follows for Hatch-Waxman suits filed under 7:24-cv-05040?

Featured snippets usually come from the complaint and any early docket entries. Without docket-text specifics, the common procedural milestones are:

• Complaint and patent list (asserted U.S. patents)
• Answer or motion practice (Fed. R. Civ. P. 12/26)
• Markman scheduling (rare in earliest phase but appears fast in some districts)
• Stay events tied to FDA exclusivity or parallel prosecution history

No actionable date or event is extractable without the docket entries.

What patents does Currax assert against Taro in 7:24-cv-05040?

Direct answer: The asserted patent numbers and claims are not provided.

What you need to know for litigation analysis (patent-by-patent)

A high-signal litigation analysis normally breaks down:

• Patent family and title (composition, method-of-use, formulation, manufacturing)
• Earliest effective priority and expiration
• Claim construction risk (functional language, dosage ranges, formulation parameters)
• Validity attack surface (102/103 obviousness art, written description, enablement, indefiniteness)
• Infringement theory (product formulation, label indications, process steps)

No asserted-patent data is available from the input.

What generic or ANDA product does Taro seek to launch in Currax v. Taro?

Direct answer: The ANDA/NDA identifier and proposed product strength, dosage form, and label are not provided.

How litigation ties to FDA filings in Hatch-Waxman cases

In these cases, the complaint and FDA-related exhibits typically map:

• The FDA submission (ANDA vs 505(b)(2), Section IV certification)
• The manufacturing site and process details
• The proposed label (method-of-use or indication-driven claims)
• The design-around allegations raised in claim charts

Those mapping elements require the FDA and complaint specifics that are not present.

Is this case based on a Paragraph IV certification or other basis for infringement?

Direct answer: The certification basis (Paragraph IV vs Paragraph I/II/III), and any alternative infringement theories (e.g., contributory or inducement) are not provided.

Why Paragraph IV basis matters for settlement dynamics

If Paragraph IV:

• early settlement is often anchored to trigger dates in patent expirations and stays
• the docket usually shows motions tied to 30-month stay, preliminary injunction requests, and negotiated “carve-outs” for product features

If non-Paragraph IV:

• liability theories may shift to label carve-outs, non-infringement, or direct vs method-of-use limitations

No certification detail is available here.

When do the asserted patents in 7:24-cv-05040 expire, and when does exclusivity end?

Direct answer: No expiration dates or exclusivity periods are provided because the asserted patents are not listed.

How to build an exclusivity and expiration timeline (what is missing)

A complete timeline typically includes:

• Each asserted U.S. patent’s expiration (including PTA where applicable)
• Any statutory exclusivity (NCE, pediatric exclusivity, orphan exclusivity where relevant)
• Any OTC/REMS label limitations if they drive method-of-use claims
• Possible manufacturing-use or process patent barriers

Those inputs require the asserted-patent identities.

What is the Orange Book status of Currax’s drug(s) implicated in the case?

Direct answer: The Orange Book listing status (patents and exclusivities tied to the NDA/ANDA) is not provided.

What an Orange Book crosswalk should show in a litigation file

A typical litigation playbook lists:

• NDA/ANDA number
• Patent numbers and listed expiration dates
• Exclusivity codes (SE, NCE, pediatric, etc.)
• Patent categorization (drug substance, drug product, method of use)

No NDA/ANDA identifier or Orange Book code is included.

What motions or key rulings occurred in 7:24-cv-05040?

Direct answer: No docket events (motions, hearings, orders, or rulings) are provided.

Litigation analysis checklist that can’t be completed without docket text

• Motion to dismiss (12(b)(6))
• Claim construction schedule
• Preliminary injunction requests and outcomes
• Procedural stays or consolidation
• Settlement dismissal orders
• Invalidation or dismissal based on unasserted claims

Without those entries, no accurate procedural narrative can be produced.

What is the settlement or injunction status in Currax v. Taro?

Direct answer: The settlement posture (dismissed, consent judgment, injunction granted/denied, delayed launch, or carve-out) is not provided.

Settlement terms typically affect launch timing and design-arounds

When settlement occurs, terms usually cover:

• permitted launch date
• scope of product design around formulation or method-of-use limitations
• label restrictions or physician guidance constraints
• royalty-bearing “license-to-market” provisions

None of those terms can be extracted from the provided data.

How strong is Currax’s patent estate in this matter?

Direct answer: Patent strength analysis cannot be computed because the asserted patents and claim scope are missing.

What a litigation-grade strength assessment requires

• Remaining term vs generic entry risk window
• Claim breadth and prosecution history
• Prior art landscape and obviousness maps
• Litigation history of the same patents or family members
• Claim construction vulnerabilities

No patent list or family data is present.

How does this dispute compare with other Taro generic patent litigations?

Direct answer: Comparison is not possible from the current input because the case’s drug, mechanism, and patent set are missing.

What a competitor benchmarking table normally includes

• Taro defendants and similar plaintiffs
• Courts and judges
• Paragraph IV wave timing
• settlement outcomes and launch dates

No such dataset can be constructed here.

What commercial launch and revenue exposure does this case create for Taro?

Direct answer: Revenue exposure cannot be quantified without:

• the implicated drug and dosage strengths
• expected market size and uptake
• planned launch date and design-around scope

What should be quantified in a production-ready exposure model

• Expected at-risk sales window
• probability-weighted infringement risk (based on claim construction and validity)
• regulatory lead time and manufacturing transfer constraints
• label impact on method-of-use claims

No product details exist here.

Key Takeaways

• The case caption and docket number are identifiable: Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited, 7:24-cv-05040.
• A litigation summary that includes asserted patents, claims, FDA basis, procedural history, rulings, settlement, and timelines cannot be produced from the information provided.
• Any high-stakes licensing, launch-timing, or litigation-risk conclusions require the complaint’s patent list and docket event record, which are not included in the prompt.

FAQs

1. What is the fastest way to determine whether Currax v. Taro is a Hatch-Waxman Paragraph IV case?
   Check the complaint’s certification language and the FDA submission identifier referenced in the allegations; none is provided here.

2. Which court rules control typical claim construction timelines in pharma patent cases like 7:24-cv-05040?
   District-specific scheduling orders govern; no judge or order dates are provided.

3. What evidence most often drives infringement findings in formulation versus method-of-use patents?
   Formulation suits typically turn on composition/analytical comparisons; method-of-use suits often turn on label and clinical/label instructions. The drug and claim type are not provided.

4. How do settlements in ANDA patent cases usually structure launch dates?
   They commonly set “no-launch” periods until specific expiration dates and/or specify label carve-outs. No settlement terms are provided.

5. What is the typical next step after a complaint in a patent infringement case?
   Defendants file a response and often early motions; subsequent steps follow the court’s scheduling order. No docket entries are provided.

References

1. U.S. District Court docket, Currax Pharmaceuticals LLC v. Taro Pharmaceutical Industries Limited, No. 7:24-cv-05040.